Using AI to improve monitoring of Kaposi Sarcoma
Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS)
This study is testing a new low-cost device that uses AI to help doctors better track and measure Kaposi Sarcoma in patients with darker skin in Uganda and Kenya.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 2 sites (Kisumu and 1 other locations) |
| Trial ID | NCT06898203 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the monitoring of Kaposi Sarcoma (KS) in Uganda and Kenya by utilizing a low-cost device called SkinScan3D (SS3D) that employs Artificial Intelligence for accurate measurement of cancer lesions. The study involves gathering feedback from healthcare workers and patients through surveys and design workshops to refine the use of the SS3D tool. By addressing the challenges of manual measurement, particularly for patients with darker skin, the study seeks to improve treatment tracking and outcomes for KS patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histopathology-confirmed Kaposi Sarcoma and at least three skin lesions who are capable of providing informed consent.
Not a fit: Patients who are not initiating treatment for Kaposi Sarcoma or those who are very ill and require hospitalization may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and equitable monitoring of Kaposi Sarcoma, ultimately improving patient outcomes.
How similar studies have performed: While the use of AI in cancer monitoring is an emerging field, this specific approach to improving KS treatment tracking has not been extensively tested, making it a novel initiative.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria - Aim 2 (Patients): * Adults age ≥18 years old * Histopathology-confirmed Kaposi Sarcoma * At least 3 skin lesions * Capable of informed consent * On treatment for Kaposi Sarcoma Exclusion Criteria - Aim 2 (Patients): * Patients not initiating Kaposi Sarcoma treatment * Very ill patients requiring hospitalization Inclusion Criteria - Aim 3 (Patients): * Adults age ≥18 years old * Histopathology-confirmed Kaposi Sarcoma * Capable of informed consent * Initiating treatment for Kaposi Sarcoma Exclusion Criteria - Aim 3 (Patients): * Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2 * Prior or ongoing Kaposi Sarcoma treatment
Where this trial is running
Kisumu and 1 other locations
- Kenya Medical Research Institute — Kisumu, Kenya (Recruiting)
- Infectious Diseases Institute, Makerere University — Kampala, Uganda (Not_yet_recruiting)
Study contacts
- Principal investigator: Thomas Odeny, MBChB, MPH, PhD — Washington University School of Medicine
- Study coordinator: Thomas Odeny, MBChB, MPH, PhD
- Email: odeny@wustl.edu
- Phone: 314-273-3022
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.